SBRT Plus Nivolumab in Advanced NSCLC: A Phase II Multicenter Study With Exploratory Bone Metastases Subgroup Analysis. (PubMed, Clin Lung Cancer) - Sep 20, 2026 - "SBRT plus nivolumab demonstrated encouraging and durable antitumor activity with manageable toxicity in previously treated advanced NSCLC. The findings concerning bone radiotherapy and serum biomarkers are exploratory and hypothesis-generating and require validation in prospective randomized studies."
Clinical • IO biomarker • Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|
|
Bo Zhu; Chenming Wei; Haowen Pang; Hua Ye; Jiawei Li; Leiya Du; Pang Jun; PeiRong Ren; Sheng Lin; Shun Gao; Yan Gui; Yan Zhang; Yiren Wang; Youhua Wang; Yu Liu; Yuhao Luo; Yunfei Li
|